SCHEMBL19834121

SCHEMBL19834121

O=C1COc2cc(F)c(C(=O)N3CC(COc4ccc(Cl)c(Cl)c4)C3)cc2N1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MGLL Q99685 5/20 0.49
▸ TP53 P04637 2/20 0.39
▸ HTR1A P08908 5/20 0.39
▸ HTR1D P28221 2/20 0.39
▸ HTR1B P28222 2/20 0.39
▸ LMNA P02545 2/20 0.39
▸ CHRNA7 P36544 1/20 0.38
▸ POLB P06746 2/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ DRD2 P14416 1/20 0.38
▸ HTR2A P28223 1/20 0.38
▸ HTR7 P34969 1/20 0.38
▸ HTR2B P41595 1/20 0.38
▸ HTR6 P50406 1/20 0.38
▸ PKM P14618 1/20 0.38
▸ MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19834134 0.95 MGLL (0.49) MGLLTP53HTR1AHTR1DHTR1B
SCHEMBL19834073 0.95 MGLL (0.49) MGLLTP53HTR1AHTR1DHTR1B
SCHEMBL19834130 0.93 MGLL (0.47) MGLLTP53HTR1AHTR1DHTR1B
SCHEMBL22386271 0.92 MGLL (0.47) MGLLTP53HTR1AHTR1DHTR1B
SCHEMBL19833976 0.92 MGLL (0.47) MGLLTP53HTR1AHTR1DHTR1B
SCHEMBL19833830 0.91 MGLL (0.48) MGLLTP53HTR1AHTR1DHTR1B
SCHEMBL19833752 0.91 MGLL (0.46) MGLLTP53HTR1AHTR1DHTR1B
SCHEMBL19833747 0.91 MGLL (0.46) MGLLTP53HTR1AHTR1DHTR1B
SCHEMBL19833878 0.90 MGLL (0.45) MGLLHTR1AHTR1DHTR1BCHRNA7
SCHEMBL19833724 0.89 MGLL (0.47) MGLLTP53HTR1AHTR1DHTR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3279191-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2020-09-02 — — EP disclosed
US-10106556-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-10-23 — — US disclosed
US-20180079756-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-03-22 — — US disclosed
US-20180079756-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-03-22 — — US disclosed
EP-3279191-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2018-02-07 — — EP disclosed
EP-3279191-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2018-02-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180079756-A1 HETEROCYCLIC COMPOUND MAG, ACHE, HTT MGLL 129/4885TP53 1722/4885HTR1A 381/4885
US-10106556-B2 Heterocyclic compound MAG, ACHE, HTT MGLL 129/4885TP53 1722/4885HTR1A 381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback